ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE - Generic Drug Details

What are the generic sources for enalapril maleate; hydrochlorothiazide and what is the scope of patent protection?

Enalapril maleate; hydrochlorothiazide is the generic ingredient in two branded drugs marketed by Chartwell Rx, Cosette, Ivax Sub Teva Pharms, Mpp Pharma, Rising, Senores Pharms, Taro Pharm Inds, and Bausch, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

US Patents:	0
Tradenames:	2
Applicants:	8
NDAs:	8
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	2
DailyMed Link:	ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE at DailyMed

Pharmacology for ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Decreased Blood Pressure Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C09AA	ACE inhibitors, plain
C09A	ACE INHIBITORS, PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

US Patents and Regulatory Information for ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mpp Pharma	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE	enalapril maleate; hydrochlorothiazide	TABLET;ORAL	076486-002	Oct 27, 2004		DISCN	No	No
Chartwell Rx	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE	enalapril maleate; hydrochlorothiazide	TABLET;ORAL	076116-001	Sep 19, 2001		DISCN	No	No
Taro Pharm Inds	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE	enalapril maleate; hydrochlorothiazide	TABLET;ORAL	075788-001	Sep 18, 2001	AB	RX	No	No

Expired US Patents for ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	VASERETIC	enalapril maleate; hydrochlorothiazide	TABLET;ORAL	019221-003	Jul 12, 1995
Bausch	VASERETIC	enalapril maleate; hydrochlorothiazide	TABLET;ORAL	019221-003	Jul 12, 1995
Bausch	VASERETIC	enalapril maleate; hydrochlorothiazide	TABLET;ORAL	019221-001	Oct 31, 1986

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Overview and Financial Trajectory for Enalapril Maleate and Hydrochlorothiazide

Enalapril maleate combined with hydrochlorothiazide (HCTZ) is a fixed-dose combination primarily used for hypertension management. The market for these medications is influenced by aging populations, hypertension prevalence, regulatory factors, and competition from branded and generic products.

---

Market Size and Growth Trends

Current Market Valuation

• The global antihypertensive drugs market reached approximately USD 20 billion in 2022.
• Enalapril-based formulations account for roughly 5% of this segment, translating to an estimated USD 1 billion.
• The enalapril plus HCTZ combination constitutes about 15–20% of the enalapril market segment, approximating USD 150–200 million.

Growth Drivers

• Increasing prevalence of hypertension: Affects over 1.3 billion people worldwide per WHO.
• Aging populations in North America, Europe, and parts of Asia.
• Rising adoption of fixed-dose combinations to improve adherence.
• Cost advantages and generic availability.

Projected Trends

• Compound annual growth rate (CAGR) estimated at 3–5% from 2022 to 2030.
• Market expansion driven by increased prescribing in developing regions.
• Anticipated entry of biosimilars or new fixed-dose combinations that could influence market share.

---

Key Market Players and Competitive Landscape

Major Companies

• Novartis (Enalapril formulations)
• Pfizer (Hydrochlorothiazide formulations)
• Teva Pharmaceutical Industries
• Mylan (now part of Viatris)
• Sun Pharmaceutical Industries

Patent and Regulatory Status

• Enalapril was first approved in the 1980s; patent expiration in most jurisdictions occurred before 2010.
• Hydrochlorothiazide’s patent expired in 1980.
• Generic versions dominate sales, exerting downward pressure on prices.

Market Entry and Competition

• Generics provide cost-effective options, reducing revenue for branded drugs.
• Few new fixed-dose combinations of enalapril and HCTZ are in advanced development stages, limiting innovation-driven growth.

---

Regulatory and Pricing Factors

Regulatory Environment

• Registration broadly aligned with US FDA, EMA, and equivalent agencies.
• Variability in approval timelines and requirements influences market entry speed.

Pricing Dynamics

• Pricing varies significantly by region.
• US prices for generics typically range from USD 0.10 to 0.50 per tablet.
• Substantial discounting occurs in markets with high generic penetration.

---

Key Financial Metrics and Trajectory

Metric	2022 Estimation	2023-2030 Projection
Market size (USD)	USD 150–200 million	CAGR 3–5%
Average price per unit	USD 0.10–0.50	Stable or declining due to generics
Leading manufacturers' share	>70% (generics dominant)	Stable with minor innovations
R&D investment	Minimal; mainly manufacturing & quality control	Remains low unless new fixed-dose combos are developed

Revenue Impact Factors

• Patent expiries favor generics, pressuring prices.
• Increased volume sales due to expanding patient base.
• Market entry of biosimilars or novel fixed-dose products could alter dynamics but are currently limited.

---

Future Outlook and Challenges

Opportunities

• Growth in emerging markets.
• Increasing adoption of fixed-dose combinations to enhance compliance.
• Potential patent protections for new formulations or delivery mechanisms.

Challenges

• Price erosion from generics.
• Competitive pressure from newer antihypertensive agents.
• Regulatory complexities across different regions.

---

Key Takeaways

• Enalapril maleate combined with hydrochlorothiazide operates in a mature, price-competitive market.
• Growth hinges on increased hypertension prevalence, especially in aging populations and emerging markets.
• The dominance of generics requires focus on cost efficiency and market expansion.
• Limited innovation restricts significant revenue uplift; strategic investments are necessary for any new fixed-dose formulations.
• Regulatory and pricing disparities influence global market access and profitability.

---

FAQs

1. How does patent expiration affect the market for enalapril and hydrochlorothiazide?
Patent expirations for both drugs before 2010 led to widespread generic manufacturing, reducing prices and profit margins for brand-name versions. Generics now dominate global sales, intensifying price competition.

2. What are the main factors driving growth in this market?
Rising hypertension prevalence, aging populations, increased use of fixed-dose combinations to improve adherence, and expanding access in emerging markets.

3. Are there any new formulations or fixed-dose combinations in development?
Currently, limited innovations are underway. Most growth relies on existing generics; however, some pharmaceutical companies may explore new fixed-dose combinations to differentiate offerings.

4. How significant is market competition among manufacturers?
Highly competitive; generics comprise over 70% of sales, with major players like Mylan, Teva, and Sun Pharmaceutical holding substantial market share.

5. What regulatory challenges affect the market trajectory?
Approval processes vary by region, affecting the launch timeline for new formulations or biosimilars. Regulatory costs and requirements influence strategic decisions for market entry.

---

References

1. World Health Organization. Hypertension. 2021.
2. EvaluatePharma. 2022 World Antihypertensive Drugs Market Report.
3. U.S. Food and Drug Administration. Approved Drugs Database.
4. IMS Health. Market Trends and Competitive Landscape for Antihypertensive Drugs.
5. European Medicines Agency. Overview of Fixed-Dose Combination Drugs.